Regulatory News - Americas
September 13, 2017 / 10:17 AM / 2 years ago

BRIEF-Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

1 Min Read

Sept 13 (Reuters) - Clovis Oncology Inc

* Clovis Oncology’s Rucaparib Ariel3 study data published in The Lancet

* Study successfully achieved primary, key secondary and exploratory endpoints​

* Plans to submit supplemental new drug application in U.S. for maintenance treatment indication in ovarian cancer by end of Oct 2017​

* In early 2018, plans to file MAA in Europe for maintenance treatment indication upon receipt of potential approval for treatment indication​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below